Pfizer and BioNTech said Thursday that they will provide 500 million doses of the COVID-19 vaccine BNT162b2 to the US government at a not-for-profit price to support immunization programs in low- and lower-middle-income countries, according to FirstWord. The companies noted that 200 million doses will be supplied this year, starting in August, with the remainder available in the first half of 2022.
The US government plans to donate the vaccine doses to 92 low- and lower-middle-income countries and economies as defined by Gavi’s COVAX Advance Market Commitment (AMC) and the 55 member states of the African Union. Pfizer and BioNTech explained that the doses are part of an earlier commitment by the companies to provide 2 billion doses of their COVID-19 vaccine to low- and middle-income countries over the next 18 months.
700 million doses shipped
BNT162b2 gained emergency-use authorization from the FDA in December last year, with the US previously reaching an agreement to pay $1.95 billion for an initial order of 100 million doses. Meanwhile, last month, Pfizer and BioNTech initiated a rolling submission to the FDA with the aim of securing full approval of the mRNA-based vaccine.
According to Pfizer and BioNTech, the companies have so far shipped 700 million doses of BNT162b2 to more than 100 countries around the world and expect to manufacture up to 3 billion doses in 2021. The drugmakers said the 500 million doses to be supplied under the latest deal with the US will be produced at facilities in the country, including Kalamazoo, MI, Andover, MA, Chesterfield, MO, Groton, CT, and McPherson, KS.